- Open Access
Liverome: a curated database of liver cancer-related gene signatures with self-contained context information
© Lee et al; licensee BioMed Central Ltd. 2011
- Published: 30 November 2011
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. A number of molecular profiling studies have investigated the changes in gene and protein expression that are associated with various clinicopathological characteristics of HCC and generated a wealth of scattered information, usually in the form of gene signature tables. A database of the published HCC gene signatures would be useful to liver cancer researchers seeking to retrieve existing differential expression information on a candidate gene and to make comparisons between signatures for prioritization of common genes. A challenge in constructing such database is that a direct import of the signatures as appeared in articles would lead to a loss or ambiguity of their context information that is essential for a correct biological interpretation of a gene’s expression change. This challenge arises because designation of compared sample groups is most often abbreviated, ad hoc, or even missing from published signature tables. Without manual curation, the context information becomes lost, leading to uninformative database contents. Although several databases of gene signatures are available, none of them contains informative form of signatures nor shows comprehensive coverage on liver cancer. Thus we constructed Liverome, a curated database of liver cancer-related gene signatures with self-contained context information.
Liverome’s data coverage is more than three times larger than any other signature database, consisting of 143 signatures taken from 98 HCC studies, mostly microarray and proteome, and involving 6,927 genes. The signatures were post-processed into an informative and uniform representation and annotated with an itemized summary so that all context information is unambiguously self-contained within the database. The signatures were further informatively named and meaningfully organized according to ten functional categories for guided browsing. Its web interface enables a straightforward retrieval of known differential expression information on a query gene and a comparison of signatures to prioritize common genes. The utility of Liverome-collected data is shown by case studies in which useful biological insights on HCC are produced.
Liverome database provides a comprehensive collection of well-curated HCC gene signatures and straightforward interfaces for gene search and signature comparison as well. Liverome is available at http://liverome.kobic.re.kr.
- Gene Signature
- Gene Search
- Query Gene
- Signature Comparison
- Database Content
Hepatocellular carcinoma (HCC) is the fifth most common and the third most deadly cancer worldwide, accounting for 600,000 deaths annually . Clinical observations have established that most HCC patients have underlying chronic liver diseases; 70-80% of HCC patients suffer from liver cirrhosis caused by chronic infection of hepatitis B virus or hepatitis C virus, excessive alcohol consumption, or certain metabolic disorders. In addition, male gender and exposure to environmental toxins such as aflatoxin increase the risk of developing HCC. Further, recent genetic and genomic studies have pointed to germline or somatic DNA alterations and specific molecular pathways for the initiation and progression of HCC. Currently, only one third of newly diagnosed HCC patients are eligible for potential curative therapies, mainly due to a lack of early detection technology and limited choices of effective therapeutic agents . Early accurate diagnosis and effective treatment of HCC require a deep understanding of how it occurs at a molecular and cellular level.
Advances in high-throughput technologies in transcriptomics and proteomics have changed the way in which HCC is studied and, potentially, diagnosed and classified in clinical practice. During the last decade, a number of molecular profiling studies have investigated changes in gene and protein expression that are induced by HCC. While early studies had focused on the comparison of expression profiles between tumorous and non-tumorous liver, later studies have more fully explored the molecular pathogenesis of HCC by associating expression changes with various clinicopathological characteristics of HCC such as etiology, prognosis, metastasis, and HCC subgroups.
The result from the molecular profiling studies most often comes in the form of a list of genes, also called a gene signature, which is reported in research articles as a table in the main text or a supplementary table. The gene signature typically consists of gene identifiers and numerical ranking information such as fold change, p-value, and other relevant statistics that describe the nature and the strength of association between the gene and the phenotype under study. Each of the gene signatures derived from profiling studies on HCC gives a distinct molecular portrait of a specific aspect of HCC under a specific sample cohort. Collective information that arises from a wealth of diverse gene signatures is expected to contribute significantly to a comprehensive understanding of molecular events underlying HCC and to the prioritization of candidate target genes for diagnosis and treatment.
Specifically, the collection of published gene signatures can be useful to liver cancer researchers in two most common situations. In one situation, a researcher may hypothesize that a particular gene is implicated in HCC and seek published evidences supporting the hypothesis. For this purpose, the candidate gene can be searched on the gene signature collection to retrieve all available differential expression evidences. If the search shows compelling evidences, the candidate gene can be further examined in depth by experimental means. In the other situation, a researcher might have performed a molecular profiling study to derive a gene signature associated with a particular phenotype under the study, for example, survival of HCC patients. Then, the derived signature can be compared with survival-associated signatures in the collection to identify common genes. Such common genes can be considered as robust marker genes that are reproducible across independent sample cohorts, and their identification can help prioritize the user-derived signature for a further in-depth validation study. To effectively serve as the gene search and signature comparison resource for liver cancer research community, we argue that a gene signature database needs to be constructed with the following considerations on web interface and database content, all of which have not been addressed by other gene signature databases currently available, such as CCancer , dbDEPC , EHCO , and GeneSigDB .
With respect to the web interface, the first aspect to consider is that the gene signature collection should be linked to both a gene search interface that retrieves differential expression information of query gene as well as a signature comparison interface that compares user-selected signatures to identify common genes for prioritization. Second, to facilitate signature comparison, the collected signatures need to be meaningfully organized for guided browsing according to their functional category, such as etiology, survival, recurrence, and differentiation. Third, it should be beneficial to give each signature an informative name for a quick recognition and easy browsing. Due to the diversity of HCC gene signatures, a cluttered collection without the meaningful organization and the informative naming would make it difficult to browse through the voluminous gene signature collection.
With respect to the database content, the first aspect to consider is that the gene signature collection should be comprehensive and up-to-date, covering most, if not all, published HCC gene signatures that associate expression changes with various characteristics of HCC. Second aspect worth considering is to present numerical ranking value in a uniform representation. Published gene signature tables present fold change values in various formats, such as ratio, log ratio, fold change with a direction tag, and a pair of intensity values. Presenting them in a uniform format will make it more intuitive to recognize similar data and make comparisons across signatures. Third, and most importantly, context information of gene signatures needs to be curated to the extent that all information is unambiguously self-contained within the database. With the availability of self-contained context information, database users would not have to refer to source articles from which the signatures were reported. The context information of a gene signature comes in two types: (i) summary of experiment that produced the gene signature, and (ii) explicit designation of compared sample groups associated with numerical ranking value (for example, fold change in poorly-differentiated samples compared to well-differentiated samples). The summary of experiment would be helpful for database users to quickly recognize detailed characteristics of gene signatures and it should document platform, clinicopathological sample characteristics, sample size, data analysis method, and others. More crucial piece of information is the explicit designation of compared sample groups associated with numerical ranking value, which is utmost essential for a correct biological interpretation of a gene’s expression change.
Collecting and extracting gene signatures
We collected 98 HCC-related profiling studies, consisting of 83 transcriptomic studies, 12 proteomic studies, and three other genome scale studies. We collected only those articles that met our collection criteria; (i) articles should report novel experimental findings (that is, we excluded review articles), (ii) the experiment should be done on HCC patients or human HCC cell lines (that is, we excluded studies done on mouse models), and (iii) the article should report gene signature tables containing enough genes (which was set arbitrarily to eight or more genes). From the main text and supplementary material of collected articles, we manually extracted gene signatures that are reported as tables (or as heatmap figures in a few cases), totalling 143 gene signatures listed in Table S1 (Additional File 1). Statistics of the gene signatures are further summarized in Table S2 (Additional File 1) with respect to ten functional categories: (1) tumor versus non-tumorous liver comparison, (2) survival/recurrence, (3) cirrhosis/dysplasia, (4) etiology, (5) differentiation, (6) invasion/metastasis, (7) genomic alterations, (8) modulation by a gene/protein factor, (9) HCC subgroups, and (10) other nature.
Post-processing the extracted signatures into uniformly formatted, informative, and self-contained form
Once the gene signature tables were extracted, we manually post-processed them to convert into a uniformly formatted, informative, and self-contained form. The conversion was made under the following four guiding principles. First, fold change values are presented in non-logarithmic ratio and non-ratio scale along with a direction tag. For example, “7.000 Down” was uniformly used to represent the reported equivalent values such as a ratio value of 0.1428, a log2 ratio value of -2.8073, a text value of ↓7.0, or a pair of intensity values of 50 and 350. Second, the column titles for fold change should explicitly designate case and control sample groups, such as tumor/normal, poor survival group/good survival group, and invasive tumor/non-invasive tumor, in which the case group is designated in the numerator and the control group in the denominator. Third, columns that give inessential information, such as the confidence interval of a test statistic, may be omitted for a succinct representation, or columns that do not exist in the original tables may be added when necessary; an example being a direction tag (up or down). Fourth, a gene signature table may be split into several signatures or several tables may be combined into one signature when appropriate. All the published gene signature tables needed to be post-processed to some extent, and attention to detail was paid throughout the post-processing to give the most informative database content, which was made possible only after first reading and understanding the source articles. The post-processing of gene signatures is a unique feature of Liverome’s database content.
In addition to the numerical ranking information, gene or protein identifiers were extracted and mapped to the most recent EntrezGene IDs using mapping files obtained from NCBI. In the absence of definite identifiers, for example when only the gene names were provided in the published signature tables, corresponding gene identifiers were acquired manually. We excluded entries that cannot be reliably mapped to EntrezGene, such as ambiguous gene names or retired UniGene IDs without further traceable information.
Annotating gene signatures: informative naming and self-contained documenting
The selected signatures are then passed to the next screen in which a combined gene signature table appears (Figure 3D), along with three additional menus in the left: export data, pathway grouping, and GO (Gene Ontology) grouping. The grouping is a simple version of enrichment analysis, in which all the present KEGG pathway or GO terms are reported without applying a p-value cutoff. For an advanced enrichment analysis, users can export the accessed gene signature to an Excel file for the use of a third party tool. Several display controls are also provided above the gene signature table, such as the one that allows viewing the number of pairwise overlapping genes between signatures [6, 8]. The most important control is “sorted by”. The order of genes in the table can be sorted by multiple columns in a sequential manner (that is, a spreadsheet-like sorting) by clicking the upward or downward arrows in the header row; the “sorted by” field shows the sorting sequence. The default ordering is set in a way that is the most reasonable under the given context, such as a descending sort on occurrence frequency followed by a sort on the gene symbol when multiple signatures are retrieved. The default ordering can be cleared by clicking “undo all sorting” and re-ordered by users. The sorting functionality should be useful to sort out the genes that are supported by multiple evidences or a particular set of evidence. An exercise on sorting is shown in the user guide on the web site.
Comparison to other resources
Comparison of Liverome with other related tools.
Coverage of phenotype
Half the data are on cancer
Mostly cancer and stem cell
Coverage of HCC-specific data (signatures // articles)
143 // 98
12 // 32
6 // 5
25 // 21
34 // 18
Overall data coverage
Same as above
Same as above
65 // 48
3369 // 2644
2142 // 973
Covers both transcriptomics and proteomics studies
No (proteomics only)
Explicit designation of compared sample groups
Contains numerical ranking information
No (change direction only)
Yes (fold change only)
Uniform representation of numerical ranking values
Yes (unique to Liverome)
Informative naming of signatures
Yes (unique to Liverome)
Summary of experiment
Yes (unique to Liverome)
Signature comparison tool
Gene search tool
Functional categorization of signatures for guided browsing
Yes (unique to Liverome)
Spreadsheet-like sorting utility for prioritization
Yes (unique to Liverome)
With respect to data coverage, Liverome’s collection of 143 HCC-related signatures from 98 articles represents a data coverage of more than four times larger (signature-wisely) and three times larger (article-wisely) than any other resource. As seen in the Venn diagram of Figure 2, two thirds of Liverome’s collection (68 articles) represents a consolidated data coverage of all other resources while one third (30 articles) is unique to Liverome. Despite the broad scope and overall large coverage attained in CCancer and GeneSigDB, their HCC-specific coverage is merely less than one quarter of Liverome, which points to the need of a gene signature database dedicated to HCC.
With respect to web interface, features unique to Liverome are functional categorization of gene signatures for guided browsing and spreadsheet-like sorting utility for occurrence-based prioritization. Liverome also has a distinctive implementation for signature comparison and gene search interfaces, which are different from corresponding interfaces implemented in other resources. The signature comparison interface of Liverome allows users to select a subset of comparable signatures of similar nature (for example, survival-associated gene signatures), whereas those of other resources do not. The gene search interface of Liverome is designed to produce a search result screen in which all information is readily readable and self-contained in one screen (Figure 4B). Obtaining such information from other resources requires reading the source articles and/or following multiple hyperlinks.
Although Liverome is superior to other resources with respect to its own utility as a gene search and signature comparison tool for liver cancer research community, the other resources also offer benefits not addressed by Liverome. CCancer enables identification of frequently co-reported gene pairs, computes signature overlap p-values, and provides by far the largest overall data coverage achieved through an automatic extraction of gene identifiers at the expense of missing numerical ranking information. GeneSigDB computes signature overlap p-values, maintains a trace of identifier mapping between the original and the re-mapped signatures, and provides a large overall data coverage even with acquisition of both gene identifiers and accompanying numerical ranking information. dbDEPC provides an explicit designation of the compared sample groups and the largest coverage of cancer-related protein signatures. All three generic resources can be a useful tool for global cross-comparison of heterogeneous cancer types. As for EHCO, the most directly comparable HCC-specific resource, we did not find any major comparative benefits that it offers. It does provide, however, a list of HCC-related genes derived through text mining, which was imported to our database as one of the collected signatures. In addition, they reported in the article an interesting post-construction analysis of protein-protein interaction network using EHCO-collected data.
To summarize, our collection of HCC-related gene signatures is the most comprehensive. Furthermore, we generated the most informative and self-contained database contents through manual post-processing and annotation, which had not been done in other databases. Our web interfaces are the most straightforward for the retrieval of well-curated differential expression information on a query gene, the guided browsing of signature collection, and the comparison of signatures for occurrence-based prioritization of common genes. In the future, we will continuously expand Liverome’s signature collection once a year by incorporating newly published HCC gene signatures. Next we demonstrate the utility of Liverome by presenting several examples in which useful biological insights on HCC are produced.
Case study 1: genes that are frequently reported among the gene signature collection in Liverome
With a database like Liverome, one natural question that can be raised is which genes are most frequently reported among the various collected gene signatures. To answer this question, we marked all 143 gene signatures from the browse and comparison interface and sorted the genes by occurrence frequency. Out of all 6,927 genes, about half of them occur in only one signature while a few genes occur frequently (Figure S1, Additional File 2). Top 22 most frequent genes occurring in 12 or more signatures are listed in Table S3 (Additional File 1).
Glypican 3 (GPC3) was identified as the third most frequently reported gene, observed in 17 gene signatures. GPC3 is a heparan sulfate proteoglycan that is attached to the cell surface by a glycosylphosphatidylinositol anchor. Previous studies have pointed to its connection to HCC. GPC3 is highly expressed in HCC , stimulates the growth of HCC cells in vitro and in vivo by activating the canonical Wnt signaling , and modulates cell proliferation through fibroblast growth factor 2 and bone morphogenetic protein 7 signaling . To confirm that the reported up-regulation of GPC3 in HCC is a frequent event and is captured by microarray studies across various platforms, we searched for GPC3 in Liverome. From the 17 gene signature hits that contain GPC3, we could easily confirm that the up-regulation of GPC3 is consistently supported by eight signatures derived from comparison of tumor with non-tumor or normal liver, along with large fold change values (Figure S2, Additional File 2). This collective information further supports the previously suggested usefulness of GPC3 as a potential diagnostic marker for HCC and a target for antibody-based therapeutic intervention of HCC .
In addition, two genes that encode enzymes in the one-carbon metabolism pathway, namely betaine-homocysteine S-methyltransferase (BHMT) and methylenetetrahydrofolate dehydrogenase 1 (MTHFD1), were identified as the fourth and seventh most frequently reported genes, observed in 16 and 13 signatures, respectively. It is known that epigenetic alterations, such as global hypomethylation, regional hypermethylation of tumor suppressor genes, and histone modification that alters chromatin structure, are involved in HCC. One-carbon metabolism, with S-adenosylmethionine (SAM) as the principal biological methyl donor, is required for the epigenetic events. Both BHMT and MTHFD1 are involved in the synthesis and regulation of SAM. Several lines of evidence have suggested that one-carbon metabolism plays an important role in HCC. First, folate/methyl-deficient rat models have shown that sufficient supply of SAM can prevent HCC development whereas chronic depletion of SAM can lead to HCC . These models also reported an altered expression of epigenetic enzymes such as DNA methyltransferases (DNMTs) and methyl CpG binding proteins (MBDs) . The aberrant regulation of DNMTs and MBDs have been observed in HCC patients and are suggested to be involved in silencing of tumor suppressor genes leading to uncontrolled cell growth and activation of metastasis genes, respectively . Second, it was reported that administration of SAM in rats reduced the expression of c-myc, Hras, and Kras oncogenes in proliferating liver cells and tumor nodules . Third, by searching for BHMT and MTHFD1 in Liverome, we could easily see that down-regulation of the two genes is prevalent in proliferative and poorly differentiated HCCs (Figures S3 and S4, Additional File 2). These evidences might shed light on the role of one-carbon metabolism genes in HCC progression, possibly through epigenetic regulation.
Case study 2: genes with somatic mutation in HCC
Next, we sought to retrieve supporting information on genes with somatic mutation in HCC using Liverome. All cancers arise from acquisition of a series of fixed DNA sequence abnormalities, many of which ultimately confer a growth advantage to the cells in which they have occurred. COSMIC (Catalogue of Somatic Mutations in Cancer) database  provides the somatic mutation information but not the gene expression information. In order to collect comprehensive data on genes with somatic mutation in HCC, we first identified frequently mutated genes in HCC from COSMIC with the following three criteria: primary tumor samples only, a minimum of 5% somatic mutation frequency, and a minimum of ten samples screened. There were eleven such genes. Upon searching for those genes on Liverome, differential expression information of eight of the genes (CSF1R, CTNNB1, CDKN2A, RB1, HNF1A, KRAS, MET, and PTEN) was retrieved (Table S4, Additional File 1), which may provide further understanding of these genes.
Case study 3: metabolic genes
ATP citrate lyase (ACLY) is a key lipogenic enzyme that catalyzes the synthesis of acetyl-CoA from mitochondria-derived citrate in the cytoplasm, a unique step that links cellular glucose catabolism and lipid synthesis. ACLY has been documented as being dramatically upregulated in a number of human carcinoma cell lines with high aerobic glycolytic activities, such as breast and bladder carcinoma . Higher glycolysis is thought to not only provide ATP for the tumor’s high energy demands, but also provide precursors for anabolic processes, including de novo fatty acid synthesis that utilizes acetyl-CoA as the initial precursor. In support of the notion that increased glycolysis contributes to enhanced carcinogenesis by providing self-produced fatty acids for membrane biosynthesis, suppression of ACLY through genetic and pharmacological approaches was shown to result in a remarkable inhibition of proliferation and differentiation of certain carcinoma cell lines . However, it is currently unclear whether the dysregulated expression of ACLY contributes to the initiation, progression, and metastasis of HCC. Interestingly, ACLY is located in chromosome 17q, a frequently amplified region in HCC tissues . By searching Liverome, we found that four gene expression studies have reported an up-regulation of ACLY in HCC (Figure S5, Additional File 2). Combined with the known functions of ACLY in other solid tumors, the information retrieved from Liverome suggests that ACLY can be a potential target for HCC treatment. In addition, through a Liverome search, we found that the glucose transporter SLC2A1 (also called GLUT1), another important player in cancer metabolism , was upregulated in AFP-positive HCC tissues and was downregulated in AFP-negative HCC tissues (Figure S6, Additional File 2). This piece of information raises the possibility that different HCC patient segments may have different GLUT1 expression level.
Case study 4: co-occurrence network analysis
Liverome database provides a comprehensive collection of well-curated HCC gene signatures and straightforward interfaces for gene search and signature comparison as well. The collected signatures were subjected to a thorough manual post-processing before inclusion into the database. Deriving a uniformly formatted and informative form of gene signatures with self-contained context information was the key aim of the post-processing. Characteristics of the gene signatures were also manually annotated to produce an informative signature naming and a detailed yet concise itemized summary. The web interface of Liverome displays gene search result in the most readable way, organizes the diverse gene signatures according to their functional categories for guided browsing, and enables their comparison to identify and prioritize common genes. Using Liverome, liver cancer researchers can have convenient access to a comprehensive and well-curated set of HCC gene signatures accumulated from a decade of molecular profiling studies on HCC. Liverome is most useful to retrieve detailed supporting evidence on a user-specified candidate gene from the published microarray and proteomic studies in HCC. The development of Liverome was initiated to compare our own gene signatures derived from microarray experiments done on a large HCC cohort in Korea (through “The 21C Frontier Functional Human Genome Project of Korea”) with publicly reported gene signatures. We found Liverome database useful for prioritizing the genes present in our own signatures for further in-depth studies. In the future, we will continuously expand Liverome’s signature collection once a year.
The database is available at http://liverome.kobic.re.kr without login requirement. All contents in Liverome are freely available for download and on-site use without restriction.
This work was supported in part by the KRIBB-Pfizer Collaboration Grant on therapeutic targets for liver and gastric cancers [IGM1601012; IGM1611012] to H.Y. and S.H. from Pfizer, Inc., and in part by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program.
This article has been published as part of BMC Genomics Volume 12 Supplement 3, 2011: Tenth International Conference on Bioinformatics – First ISCB Asia Joint Conference 2011 (InCoB/ISCB-Asia 2011): Computational Biology. The full contents of the supplement are available online at http://www.biomedcentral.com/1471-2164/12?issue=S3.
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.View ArticlePubMedGoogle Scholar
- Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology. 2005, 42: 1208-1236. 10.1002/hep.20933.View ArticlePubMedGoogle Scholar
- Dietmann S, Lee W, Wong P, Rodchenkov I, Antonov AV: CCancer: a bird's eye view on gene lists reported in cancer-related studies. Nucleic Acids Res. 2010, 38: W118-W123. 10.1093/nar/gkq515.PubMed CentralView ArticlePubMedGoogle Scholar
- Li H, He Y, Ding G, Wang C, Xie L, Li Y: dbDEPC: a database of differentially expressed proteins in human cancers. Nucleic Acids Res. 2010, 38: D658-D664. 10.1093/nar/gkp933.PubMed CentralView ArticlePubMedGoogle Scholar
- Hsu CN, Lai JM, Liu CH, Tseng HH, Lin CY, Lin KT, Yeh HH, Sung TY, Hsu WL, Su LJ, Lee SA, Chen CH, Lee GC, Lee DT, Shiue YL, Yeh CW, Chang CH, Kao CY, Huang CY: Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma genes Online). BMC Bioinformatics. 2007, 8: 66-10.1186/1471-2105-8-66.PubMed CentralView ArticlePubMedGoogle Scholar
- Culhane AC, Schwarzl T, Sultana R, Picard KC, Picard SC, Lu TH, Franklin KR, French SJ, Papenhausen G, Correll M, Quackenbush J: GeneSigDB—a curated database of gene expression signatures. Nucleic Acids Res. 2010, 38: D716-D725. 10.1093/nar/gkp1015.PubMed CentralView ArticlePubMedGoogle Scholar
- Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J: Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005, 5: 45-10.1186/1471-2407-5-45.PubMed CentralView ArticlePubMedGoogle Scholar
- Jeong SK, Kwon MS, Lee EY, Lee HJ, Cho SY, Kim H, Yoo JS, Omenn GS, Aebersold R, Hanash S, Paik YK: BiomarkerDigger: a versatile disease proteome database and analysis platform for the identification of plasma cancer biomarkers. Proteomics. 2009, 9: 3729-3740. 10.1002/pmic.200800593.View ArticlePubMedGoogle Scholar
- Hsu HC, Cheng W, Lai PL: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997, 57: 5179-5184.PubMedGoogle Scholar
- Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer. 2003, 103: 455-465. 10.1002/ijc.10856.View ArticlePubMedGoogle Scholar
- Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005, 18: 1591-1598.PubMedGoogle Scholar
- Pogribny IP, James SJ, Jernigan S, Pogribna M: Genomic hypomethylation is specific for preneoplastic liver in folate/methyl deficient rats and does not occur in non-target tissues. Mutat Res. 2004, 548: 53-59. 10.1016/j.mrfmmm.2003.12.014.View ArticlePubMedGoogle Scholar
- Ghoshal K, Li X, Datta J, Bai S, Pogribny I, Pogribny M, Huang Y, Young D, Jacob ST: A folate- and methyl-deficient diet alters the expression of DNA methyltransferases and methyl CpG binding proteins involved in epigenetic gene silencing in livers of F344 rats. J Nutr. 2006, 136: 1522-1527.PubMed CentralPubMedGoogle Scholar
- Szyf M: Therapeutic implications of DNA methylation. Future Oncol. 2005, 1: 125-135. 10.1517/14796622.214.171.124.View ArticlePubMedGoogle Scholar
- Pascale RM, Simile MM, Satta G, Seddaiu MA, Daino L, Pinna G, Vinci MA, Gaspa L, Feo F: Comparative effects of L-methionine, S-adenosyl-L-methionine and 5'-methylthioadenosine on the growth of preneoplastic lesions and DNA methylation in rat liver during the early stages of hepatocarcinogenesis. Anticancer Res. 1991, 11: 1617-1624.PubMedGoogle Scholar
- Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA: COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010, 38: D652-D657. 10.1093/nar/gkp995.PubMed CentralView ArticlePubMedGoogle Scholar
- Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 2008, 68: 8547-8554. 10.1158/0008-5472.CAN-08-1235.View ArticlePubMedGoogle Scholar
- Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB: ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005, 8: 311-321. 10.1016/j.ccr.2005.09.008.View ArticlePubMedGoogle Scholar
- Furge KA, Dykema KJ, Ho C, Chen X: Comparison of array-based comparative genomic hybridization with gene expression-based regional expression biases to identify genetic abnormalities in hepatocellular carcinoma. BMC Genomics. 2005, 6: 67-10.1186/1471-2164-6-67.PubMed CentralView ArticlePubMedGoogle Scholar
- Amann T, Hellerbrand C: GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets. 2009, 13: 1411-1427. 10.1517/14728220903307509.View ArticlePubMedGoogle Scholar
- Langfelder P, Horvath S: WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008, 9: 559-10.1186/1471-2105-9-559.PubMed CentralView ArticlePubMedGoogle Scholar
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005, 102: 15545-15550. 10.1073/pnas.0506580102.PubMed CentralView ArticlePubMedGoogle Scholar
- Daskalow K, Pfander D, Weichert W, Rohwer N, Thelen A, Neuhaus P, Jonas S, Wiedenmann B, Benckert C, Cramer T: Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol. 2009, 132: 21-31. 10.1007/s00418-009-0590-4.View ArticlePubMedGoogle Scholar
- Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005, 65: 613-621.View ArticlePubMedGoogle Scholar
- Lamb JR, Zhang C, Xie T, Wang K, Zhang B, Hao K, Chudin E, Fraser HB, Millstein J, Ferguson M, Suver C, Ivanovska I, Scott M, Philippar U, Bansal D, Zhang Z, Burchard J, Smith R, Greenawalt D, Cleary M, Derry J, Loboda A, Watters J, Poon RTP, Fan ST, Yeung C, Lee NPY, Guinney J, Molony C, Emilsson V, Buser-Doepner C, Zhu J, Friend S, Mao M, Shaw PM, Dai H, Luk JM, Schadt EE: Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS ONE. 2011, 6: e20090-10.1371/journal.pone.0020090.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.